Investment

Zacks Investment Research Brokers Raise Earnings Estimates for Tenax Therapeutics, Inc. (NASDAQ:TENX)


Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) – Investment analysts at Zacks Investment Research upped their FY2022 earnings per share estimates for Tenax Therapeutics in a note issued to investors on Thursday, May 19th. Zacks Investment Research analyst J. Vandermosten now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.44) for the year, up from their prior forecast of ($0.56). Zacks Investment Research also issued estimates for Tenax Therapeutics’ FY2023 earnings at ($0.53) EPS and FY2024 earnings at ($0.46) EPS.

Separately, StockNews.com started coverage on Tenax Therapeutics in a research note on Saturday. They issued a “sell” rating on the stock.

NASDAQ TENX opened at $0.64 on Monday. The stock has a market capitalization of $16.03 million, a PE ratio of -0.26 and a beta of 2.00. Tenax Therapeutics has a 1 year low of $0.50 and a 1 year high of $2.30. The business’s 50-day moving average is $0.67 and its 200 day moving average is $0.85.

A hedge fund recently raised its stake in Tenax Therapeutics stock. Morgan Stanley grew its holdings in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) by 1,932,400.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 38,650 shares of the specialty pharmaceutical company’s stock after purchasing an additional 38,648 shares during the period. Morgan Stanley owned approximately 0.15% of Tenax Therapeutics worth $80,000 as of its most recent SEC filing. 32.00% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics (Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

Recommended Stories



Receive News & Ratings for Tenax Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tenax Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button